SCHEMBL6804776

SCHEMBL6804776

NCCCNCCCNCC(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.52
CA12 O43570 3/20 0.52
CA2 P00918 3/20 0.52
CA4 P22748 3/20 0.52
CA6 P23280 3/20 0.52
CA5A P35218 3/20 0.52
CA7 P43166 3/20 0.52
CA9 Q16790 3/20 0.52
CA14 Q9ULX7 3/20 0.52
CA5B Q9Y2D0 3/20 0.52
ALOX15 P16050 3/20 0.52
KMT2A Q03164 3/20 0.52
CASP2 P42575 2/20 0.52
F13A1 P00488 2/20 0.52
THPO P40225 2/20 0.52
MEN1 O00255 2/20 0.52
RECQL P46063 2/20 0.52
CYP2C19 P33261 1/20 0.52
HSD17B10 Q99714 1/20 0.52
MAOA P21397 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7984820 0.98 CYP1A2 (0.56) CYP1A2CA12CA2CA4CA6
SCHEMBL93783 0.95
Hydrochloric Acid SCHEMBL16227633 0.93 MAOA (0.54) CYP1A2CA12CA2CA4CA6
SCHEMBL28831589 0.93 MAOA (0.54) CYP1A2CA12CA2CA4CA6
SCHEMBL7700013 0.89 MAOA (0.67) CYP1A2CA12CA2CA4CA6
SCHEMBL163406 0.88 MAOA (0.65) CYP1A2CA12CA2CA4CA6
SCHEMBL288829 0.86 MAOA (0.69) CYP1A2CA12CA2CA4CA6
SCHEMBL181523 0.86 MAOA (0.69) CYP1A2CA12CA2CA4CA6
SCHEMBL13154751 0.86 KMT2A (0.61) CYP1A2CA12CA2CA4CA6
SCHEMBL11113096 0.86 MAOA (0.63) CYP1A2CA12CA2CA4CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160368878-A1 REDUCTION-TRIGGERED ANTIBACTERIAL SIDEROMYCINS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-12-22 US disclosed
US-20160319322-A1 PATHOGEN DETECTION UNIVERSITY OF NOTRE DAME DU LAC (US) 2016-11-03 US disclosed
US-20040132707-A1 Catecholate beta-lactam conjugates, method for producing the same and the use thereof GRUENENTHAL GMBH (DE) 2004-07-08 US disclosed
EP-1370296-A2 CATECHOLATE BETA-LACTAM CONJUGATES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF Grünenthal GmbH (DE) 2003-12-17 EP disclosed
WO-2002085841-A2 SUBSTITUTED CATECHOL DERIVATIVES DERIVED FROM POLYBASIC SECONDARY AMINO ACIDS, METHOD FOR PRODUCTION AND USE THEREOF Grünenthal GmbH (DE) 2002-10-31 WO disclosed
WO-2002070016-A2 CATECHOLATE BETA-LACTAM CONJUGATES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF Grünenthal GmbH (DE) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132707-A1 Catecholate beta-lactam conjugates, method for producing the same and the use thereof COMT, CAT, SLC7A11 CYP1A2 1276/4885CA12 275/4885CA2 774/4885
US-20160368878-A1 REDUCTION-TRIGGERED ANTIBACTERIAL SIDEROMYCINS HAMP, SLC40A1, FTH1 CYP1A2 2004/4885CA12 2253/4885CA2 2848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.